Krystal Biotech (NASDAQ:KRYS) Trading Up 7.1% After Analyst Upgrade

Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) shares shot up 7.1% during trading on Thursday after Citigroup raised their price target on the stock from $206.00 to $215.00. Citigroup currently has a neutral rating on the stock. Krystal Biotech traded as high as $186.69 and last traded at $188.63. 82,372 shares traded hands during mid-day trading, a decline of 66% from the average session volume of 244,607 shares. The stock had previously closed at $176.17.

A number of other analysts also recently commented on the company. Cantor Fitzgerald reissued an "overweight" rating and issued a $215.00 price objective on shares of Krystal Biotech in a research note on Thursday. HC Wainwright reissued a "buy" rating and issued a $221.00 price objective on shares of Krystal Biotech in a research note on Wednesday. Finally, Chardan Capital boosted their target price on Krystal Biotech from $212.00 to $218.00 and gave the stock a "buy" rating in a research report on Thursday. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $210.00.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the transaction, the insider now owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. The trade was a 1.67 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 14.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Wilmington Savings Fund Society FSB purchased a new position in shares of Krystal Biotech during the third quarter valued at $40,000. Values First Advisors Inc. purchased a new position in shares of Krystal Biotech during the third quarter valued at $53,000. GF Fund Management CO. LTD. purchased a new position in shares of Krystal Biotech during the fourth quarter valued at $95,000. Huntington National Bank grew its holdings in shares of Krystal Biotech by 97.6% during the third quarter. Huntington National Bank now owns 573 shares of the company's stock valued at $104,000 after buying an additional 283 shares in the last quarter. Finally, Blue Trust Inc. grew its holdings in shares of Krystal Biotech by 242.4% during the third quarter. Blue Trust Inc. now owns 582 shares of the company's stock valued at $107,000 after buying an additional 412 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company's stock.

Krystal Biotech Price Performance

The firm has a market cap of $5.40 billion, a PE ratio of 62.83 and a beta of 0.84. The business has a fifty day moving average price of $157.37 and a two-hundred day moving average price of $175.23.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating analysts' consensus estimates of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The firm had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. During the same quarter in the previous year, the company posted $0.30 earnings per share. The business's quarterly revenue was up 116.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).